Iptacopan in Patients With IgA Nephropathy From East Asia.

ABSTRACT:

Introduction

IgA nephropathy (IgAN) has a high risk of progression to kidney failure in East Asia. At the month 9 interim analysis (IA) of the APPLAUSE-IgAN trial, iptacopan, a complement factor B inhibitor, demonstrated a -38.3% change from baseline in 24-hour urine protein-to-creatinine ratio (UPCR) versus placebo and had a favorable safety profile. Considering the IgAN clinical burden in East Asia, we report APPLAUSE-IgAN IA findings from East Asian patients.

Methods

APPLAUSE-IgAN was a phase 3 trial (NCT04578834) in adults with biopsy-confirmed IgAN and 24-hour UPCR ≥ 1 g/g despite optimized supportive care. Patients were randomized to iptacopan 200 mg or placebo twice daily. Interim efficacy was assessed in the first 250 patients who remained in or discontinued the tria

SUBMITTER: Zhang H 

PROVIDER: S-EPMC12799516 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature